Navigation Links
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Date:8/18/2008

BEIJING, Aug. 18 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical company in the People's Republic of China ("PRC"), today announced financial results for the quarter and six months ended June 30, 2008.

Second Quarter 2008 Highlights

-- Total revenues increased to $19.4 million, up 51.4% from the second

quarter of 2007

-- Gross profit was $9.7 million, up 76.4% from the second quarter of 2007,

and gross margin was 50.0% compared to 42.9% in the second quarter of

2007

-- Net income was $2.2 million, or $0.05 per diluted share, compared to

$3.0 million, or $0.07 per diluted share, in the second quarter of 2007

-- Excluding non-cash financing costs, adjusted net income was $2.5

million, or $0.06 per fully diluted share, compared to adjusted net

income of $3.4 million, or $0.08 per fully diluted share, in the second

quarter of 2007

-- Obtained the patent and the exclusive production rights for

Laevo-Bambutero, an asthma drug

-- Placed a down payment for land rights in Inner Mongolia and plan to

build a new manufacturing facility

"We are pleased with our revenue and gross margin results in the second quarter and first six months of 2008. Wholesale distribution was strong throughout the first half of 2008 for products which we produce and pharmaceutical products which we distribute that are produced by third-party manufacturer. Much of our revenue growth last quarter was the result of a sales incentive program that temporarily offered our sales people higher than usual sales commissions," said Dr. Zhongyi Liu, Chairman and CEO of Lotus Pharmaceuticals, Inc. "We continued to develop and acquire new pharmaceutical products throughout the second quarter and first six months of 2008 while supporting our current products and growing distribution network
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , Dec. ... PTBIW), a biopharmaceutical company advancing patient care in critical ... of 3,500,000 shares of common stock, and warrants to ... stock, at an offering price of $4.00 per share ... share exercise price of $5.00, are exercisable immediately, and ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ... the revenue and share analysis. , Full ...
(Date:12/24/2014)... December 23, 2014 ... is designed to introduce cutting edge communication ... and partners of platform upgrades. This webinar ... empowering users in their quest to leverage ... , According to SoundConnect’s Marketing Manager, Seanna ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Data published in July 7, 2009 Issue ... Sciences, , , QUEBEC CITY, July 7 /PRNewswire-FirstCall/ - ... a global biopharmaceutical company focused on endocrine therapy and oncology, ... of the National Academy of Sciences (PNAS), of new data ...
... , THE WOODLANDS, Texas, July 7 Lexicon ... biopharmaceutical company focused on discovering and developing breakthrough treatments for ... 2 clinical trial of LX1032 , the ... carcinoid syndrome . LX1032 is designed ...
... ... and investigators at the Burnham Institute for Medical Research at Lake Nona (Burnham) announced ... microbial compounds that have potential as tools for biological research and ultimately the discovery ... ...
Cached Biology Technology:AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 2AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 3AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 4Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 2Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 3Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 4Burnham Institute for Medical Research and Magellan BioScience Group, Inc. Announce Drug Discovery Collaboration 2Burnham Institute for Medical Research and Magellan BioScience Group, Inc. Announce Drug Discovery Collaboration 3
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major ... demand for medical sensors in biomedical applications. Chemical ... quick and correct diagnosis during surgical procedures. The ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... snuggle can prematurely end a love affair, as new evidence ... a smokers risk of an early heart attack. Researchers say ... population has a gene defect that delivers a one-two punch ... with this common gene variant experienced a heart attack around ...
... chance Lake Mead, a key source of water for millions ... by 2021 if climate changes as expected and future water ... at Scripps Institution of Oceanography, UC San Diego. ... River system has no buffer to sustain the population of ...
... U.S. Department of Homeland,Security (DHS) announced today ... international visitors arriving at San Francisco,International Airport ... the,department,s upgrade from two- to 10-fingerprint collection ... more accurately and,efficiently establishing and verifying visitors, ...
Cached Biology News:Cigarette after Valentine snuggle deadlier for some 2Cigarette after Valentine snuggle deadlier for some 3Lake Mead could be dry by 2021 2Lake Mead could be dry by 2021 3DHS Begins Collecting 10 Fingerprints From International Visitors at San Francisco International Airport 2
... form culture flask is designed for culturing organisms requiring ... has a heavy beaded rim to protect against chipping ... is 38mm and takes a No. 6.5 rubber stopper. ... heat source smaller than the base of the flask. ...
... to achieve in many bacterial strains due ... restriction and modification (R-M) systems that cleave ... TypeOne™ Restriction Inhibitor provides a powerful method ... with type I R-M systems. Developed ...
... cassette is designed to allow chloramphenicol ... prokaryotic promoter gb2 driving the gene ... modified version of the Em7 promoter. ... the generally used Tn5 promoter. A ...
Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...
Biology Products: